The ANGIOPREDICT prospective translational study is an Exploratory Phase II clinical trial comprising biomarker analysis of oxaliplatin plus fluorouracil/leucovorin (FOLFOX) in combination with bevacizumab (bvz) in first line treatment of metastatic colorectal cancer (CRC) expressing mutant K-ras – AC-ANGIOPREDICT’.
Integrative methods for prostate cancer research: bridging molecular and population science on 14 June 2013.
This one-day course will provide in-depth exposure to fundamentals of epidemiology and molecular pathology of prostate cancer.
Each year the International Clinical Trials Day is celebrated around the world on or near the 20th of May to celebrate the day that James Lind began his controlled trial comparing the different treatments for scurvy on the 20th May 1747.
8th May 2013 is the first World Ovarian Cancer Day. Ovarian cancer has the lowest survival rate of all gynecologic cancers, and is characterized around the world by a lack of awareness of symptoms and late stage diagnosis.
ICORG is now availablie on the list of charities listed on iDonate.ie
ICORG is now registered in the list of charities available on MyCharity.ie
ICORG is proud to play an important role in the development of a Significant new cancer medicine – Palbociclib – for the treatment of advanced/metastatic breast cancer.
A Two Day Course outlining the Principles and Practice of Modern Multidisciplinary Translational Cancer Research will take place on Friday 19th & 26th April 2013 in NICB Seminar Room, Dublin City University.
Dr. Dennis Slamon – one of the foremost cancer researchers in the world today – will give a public talk on Thursday 28th February 2013 at 8pm in JM Synge Lecture Theatre, Trinity College Dublin.